Full statement by Johnson & Johnson as COVID-19 clinical trial is paused due to illness

Although we are headquartered in Washington D.C. USA, our reporters and editors are working around the globe to cover what you care about. We invite you to donate to our fundraiser to help us keep our quality news free and available to all.  

This is a full statement by Johnson & Johnson after it temporarily paused All dosing in Janssen COVID-19 vaccine candidate clinical trials

At Johnson & Johnson, there is no greater priority than the safety and well being of the people we serve every day around the world. We are committed to providing transparent updates throughout the clinical development process of our vaccine candidate, in compliance with regulatory standards and our own high ethical and scientific principles.

We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant. Following our guidelines, the participant’s illness is being reviewed and evaluated by the ENSEMBLE independent Data Safety Monitoring Board (DSMB) as well as our internal clinical and safety physicians.

[read_more id="2" more="Read full article" less="Read less"]

Adverse events – illnesses, accidents, etc. – even those that are serious, are an expected part of any clinical study, especially large studies. Based on our strong commitment to safety, all clinical studies conducted by the Janssen Pharmaceutical Companies of Johnson & Johnson have prespecified guidelines. These ensure our studies may be paused if an unexpected serious adverse event (SAE) that might be related to a vaccine or study drug is reported, so there can be a careful review of all of the medical information before deciding whether to restart the study.

We must respect this participant’s privacy. We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.

SAEs are not uncommon in clinical trials, and the number of SAEs can reasonably be expected to increase in trials involving large numbers of participants. Further, as many trials are placebo-controlled, it is not always immediately apparent whether a participant received a study treatment or a placebo.

“Study Pause” vs. “Regulatory Hold:” What’s the Difference?

While these terms are sometimes used interchangeably, there is a significant distinction between a study pause and a regulatory hold of a clinical trial.

  • study pause, in which recruitment or dosing is paused by the study sponsor, is a standard component of a clinical trial protocol.As noted in the ENSEMBLE study protocol, Johnson & Johnson has robust mechanisms in place to protect the safety of participants in its clinical trials. While the Company informs all study investigators, we typically do not communicate study pauses publicly.
  • regulatory hold of a clinical trial is a requirement by a regulatory health authority, such as the U.S. Food and Drug Administration (FDA). As outlined in our transparency commitments, we proactively disclose any regulatory hold of a pivotal clinical trial.

Notice to Investors Concerning Forward-Looking Statements
This contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding development of potential preventive regimens for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.govwww.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

[/read_more]

Today News Africa
Today News Africahttps://todaynewsafrica.com
TODAY NEWS AFRICA is registered and headquartered in Washington, District of Columbia, United States of America. Our publication is widely read, respected and influential. By providing daily answers to questions our readers have about the people, the businesses and the continent of Africa, we are reaching a diverse and wide audience from around the world. Our readers, many of them world leaders, trust us because we are independent and truthful. Our advertisers understand the difference between news, views and ads. Contact us: contactus@todaynewsafrica.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Trending Now

DR Congo rebel commander wanted for multiple crimes still a free man

Congolese authorities have not arrested a rebel commander wanted for multiple crimes under a June 2019 warrant even as his forces have...

Trump says Sudan to be removed from terrorism list if it pays $335 million in compensation

President Donald Trump on Monday said Sudan will be removed from the U.S. list of state sponsors of terrorism once it...

Anxiety in Africa as Johnson & Johnson conceals critical details about COVID-19 vaccine illness

Anxiety continued to mount across Sub-Saharan Africa on Monday over COVID-19 vaccine trials by Johnsons & Johnson, as the company continued...

Rights group urges AU to denounce crackdown on Cameroon’s opposition

Human Rights Watch on Monday urged the African Union (AU), the African Commission on Human and Peoples’ Rights (ACHPR), the Economic...

Mass prison break: Thugs disguised as protesters free over 200 inmates in Nigeria

Thugs disguised as protesters have freed over 200 inmates in Nigeria.The criminals disguised as EndSARS protesters freed...

MOST POPULAR

Damning report finds detainees in Iran were sexually abused and given electric shocks in gruesome post-protest crackdown

Iran’s police, intelligence and security forces, and prison officials have committed, with the complicity of judges and prosecutors, a catalogue of...

Africa shocked U.S. under Trump has worst coronavirus response in the world

President Donald Trump has "failed in his basic duty to protect Americans", world's renowned journalist Bob Woodward told Fox News Sunday...

IMF’s Georgieva says second round of support coming to Africa but Oxfam argues debt cancelation the only way out of COVID-19 turmoil

The Managing Director of the International Monetary Fund (IMF) Ms. Kristalina Georgieva said on Wednesday that the Washington DC-based institution is...

Johnson & Johnson vaccine trial taking place in South Africa halted by participant’s illness

Johnson & Johnson confirmed on Monday that it had paused its COVID-19 vaccine study because one of its participants was taken...

EXCLUSIVE: IMF economist details how COVID-19 economic turmoil in Asia will affect Sub-Saharan Africa

The COVID-19 pandemic is battering economies in Asia with a contraction expected for the first time in many decades. The economic...

Trump says Sudan to be removed from terrorism list if it pays $335 million in compensation

President Donald Trump on Monday said Sudan will be removed from the U.S. list of state sponsors of terrorism once it pays $335 million in compensation to American terror victims and their families.Trump said in a tweet that the Sudanese government agreed to pay the $ 335 million in compensation for victims of terrorism, adding that once the...

[/read_more]

[read_more id="2" more="Read full article" less="Read less"]

Share
Tweet
WhatsApp
Reddit
Share